Skip to Content
Merck
All Photos(2)

Key Documents

SAB4300531

Sigma-Aldrich

Anti-BCL2L11 (Ab-69) antibody produced in rabbit

affinity isolated antibody

Synonym(s):

Anti-BAM antibody produced in rabbit, Anti-BCL2-like 11 (apoptosis facilitator) antibody produced in rabbit, Anti-BIM antibody produced in rabbit, Anti-BIM-alpha6 antibody produced in rabbit, Anti-BIM-beta6 antibody produced in rabbit

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

~23 kDa

species reactivity

rat, human, mouse

concentration

1 mg/mL

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:100
western blot: 1:500-1:1000

isotype

IgG

immunogen sequence

(P-A-S-P-G)

NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... BCL2L11(10018)

General description

Bcl-2(B-cell lymphoma 2)-like protein 11 (BCL2L11) also known as Bcl-2 interacting mediator of cell death (BIM), belongs to BH3-only death activator family. In human chromosome, the gene BCL2L11 is localized on 2q13.

Immunogen

Peptide sequence around aa. 67-71 (P-A-S-P-G), according to the protein BCL2L11.

Biochem/physiol Actions

Bcl-2-like protein 11 (BCL2L11) is a key factor for determining the cell fate in the absence of cytokines. BCL2L11 is a pro-apoptotic protein, which initiates intrinsic apoptotic pathway and causes apoptosis. BIM initiates apoptosis upon upregulation by tyrosine kinase inhibitors (TKI) and binds to pro-survival Bcl2 family through its SH3 domain. BIM is a key factor to evaluate cancer therapy outcomes. Downregulation of BCL2L11 by either polymorphism or promoter hypermethylation, results in survival of chronic myeloid leukaemia cells and also provides drug resistance. BCL2L11 is associated with lymphomagenesis. Upregulation of MicroRNA (miR-24) suppresses BCL2L11 expression in gastrointestinal tumour, promotes cell proliferation and invasion.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Target description

Induces apoptosis. Isoform BimL is more potent than isoform BimEL. Isoform Bim-alpha1, isoform Bim-alpha2 and isoform Bim-alpha3 induce apoptosis, although less potent than the isoforms BimEL, BimL and BimS. Isoform Bim-gamma induces apoptosis.

Physical form

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer
Zhang H, et al
Protein & cell, 7(2), 141-151 (2016)
Molecular pathogenesis of mantle cell lymphoma
Jares P, et al.
The Journal of Clinical Investigation, 122(10), 3416-3423 (2012)
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia
Leo E, et al.
British Journal of Haematology, 159(3), 373-376 (2012)
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium
Nieters A, et al.
Blood, 120, 4645-4648 (2012)
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
Soh SX, et al.
Oncotarget, 8(25), 41474-41486 (2017)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service